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Factor VIII is a procofactor that plays a critical role
inbloodcoagulation, and ismissingordefective in he-
mophilia A.We determined the X-ray crystal structure
of B domain-deleted human factor VIII. This protein is
composed of five globular domains and contains
one Ca2+ and two Cu2+ ions. The three homologous
A domains form a triangular heterotrimer where the
A1 and A3 domains serve as the base and interact
with the C2 and C1 domains, respectively. The struc-
turally homologous C1 and C2 domains reveal
membrane binding features. Based on biochemical
studies, amodel of the factor IXa-factor VIIIa complex
was constructed by in silico docking. Factor IXa
wraps across the side of factor VIII, and an extended
interface spans the factor VIII heavy and light chains.
This model provides insight into the activation of
factor VIII and the interaction of factor VIIIa with factor
IXa on the membrane surface.
INTRODUCTION
Factor VIII is a protein cofactor that, when activated, forms a
complex with factor IXa onmembrane surfaces to activate factor
X during blood coagulation (Furie and Furie, 1988). This glyco-
protein is encoded by a gene of 186 kb that is divided into 26
exons (Gitschier et al., 1984; Toole et al., 1984). Factor VIII is syn-
thesized as a single polypeptide chain, including a 19 residue
signal peptide. The mature factor VIII contains 2332 amino acid
residues arranged within six domains organized as A1-A2-B-
A3-C1-C2 (Gitschier et al., 1984; Toole et al., 1984; Figure 1A).
Factor VIII circulates in the blood as a heterodimer composed
of two polypeptide chains: a light chain with a molecular weight
of 80,000 and a heterogeneous heavy chain with a molecular
weight varying between 90,000 and 200,000, both derived
from the single peptide chain. A region of the C2 domain con-
tains a membrane binding site of factor VIII and the site of inter-
action with vonWillebrand factor (Pratt et al., 1999). Factor VIII is
inactive or minimally active as a cofactor in blood coagulation,
but is converted into its active cofactor form by proteolytic cleav-
age. Although active factor VIII can be formed from cleavage at
Arg372 and Arg1689, and these are essential for cofactor activa-Structuretion, fully active factor VIII is generated by three cleavage events
involving Arg372, Arg740, and Arg1689 (Pittman and Kaufman,
1988).
Hemophilia A is caused by a defect in the factor VIII gene that
leads to diminished or absent factor VIII activity in blood. A het-
erogeneous genetic disease, hemophilia A, has been associated
withmissensemutations, nonsensemutations, gene deletions of
varying size, inversions, and splice junction mutations (Furie and
Furie, 1990; Graw et al., 2005). The major treatment of the bleed-
ing disorder associated with hemophilia A is the infusion of factor
VIII, which leads to the correction of hemostasis (Mannucci and
Tuddenham, 2001; Key and Negrier, 2007). The B domain of por-
cine factor VIII shows no sequence homology to the B domain of
human factor VIII, yet porcine and human factor VIII have similar
specific coagulant activities when evaluated in human plasma.
Based upon this observation, engineered B domain-deleted hu-
man factor VIII was generated and shown to have full biological
activity, and could be expressed in heterologous cells with im-
proved expression efficiency relative to that of the full-length
molecule (Toole et al., 1986). The structural heterogeneity of B
domain-deleted factor VIII is significantly less than that for full-
length factor VIII, with a heavy chain of 90,000 MW and a light
chain of 80,000 MW (Figure 1A).
Electron microscopy of human factor VIII utilizing rotary shad-
owing revealed a globular structure of 14 nm diameter, with
satellite appendages (Fowler et al., 1990), whereas scanning
transmission electron microscopic images of porcine factor VIII
indicated a globular core structure of 10–12 nm, also with satel-
lite structures, possibly assigned to the B domain (Mosesson
et al., 1990). Crystallization of the human factor VIII C2 domain
has revealed a domain of factor VIII at high atomic resolution
(Pratt et al., 1999). Recently, the intermediate resolution X-ray
crystallographic structure of a B-domainless factor VIII has
been reported (Shen et al., 2008), and describes the tertiary
structure and the domain organization. Other efforts to better
understand the structure of factor VIII in the absence of X-ray
crystallographic data have been based on homology modeling
with related structures of the A domain (Pan et al., 1995; Pember-
ton et al., 1997), the C domains (Pellequer et al., 1998), and the
structural organization of both ceruloplasmin (Zaitseva et al.,
1996) and activated protein C-inactivated factor Va (Adams
et al., 2004).
To better understand the critical role that factor VIII plays in the
tenase complex during blood coagulation, we have determined
the three-dimensional structure of B domain-deleted factor VIII16, 597–606, April 2008 ª2008 Elsevier Ltd All rights reserved 597
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Structure of Blood Coagulation Factor VIIIFigure 1. Crystal Structure of B Domain-Deleted Factor VIII
(A) Diagram of the domain organization of human factor VIII and the B domain-deleted factor VIII.
(B) Three-dimensional structure of B domain-deleted factor VIII. The A1 domain (residues 1–336) and the a1 acidic region (residues 337–372) are colored dark
blue. The A2 domain (residues 373–710) and the a2 acidic region (residues 711–740) are colored light blue. These regions (A1, a1, A2, a2) comprise the heavy
chain. The A3 domain (residues 1690–2019), the C1 domain (residues 2020–2172), and the C2 domain (residues 2173–2332) comprise the light chain and are
colored red, dark pink, and light pink, respectively. The a3 acidic region is disordered and not included in this structure. The structure contains two Cu2+ ions
(green), one Ca2+ ion (orange), and three carbohydrate moieties (gray).598 Structure 16, 597–606, April 2008 ª2008 Elsevier Ltd All rights reserved
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Structure of Blood Coagulation Factor VIIIat atomic resolution by X-ray crystallography and have gener-
ated an in silico model of the factor IXa-factor VIIIa complex.
RESULTS AND DISCUSSION
Structure of Factor VIII
Themature B domain-deleted human factor VIII used for crystal-
lization contains residues 1–740 that comprise the heavy chain
(A1 and A2 domains), a short peptide linker (residues 741–754)
and residues 1649–2332 that comprise the light chain (A3, C1,
and C2 domains; Figure 1A; Sandberg et al., 2001). The protein
crystallized in the tetragonal space group P41212 with an unusu-
ally high solvent content of 75% (Table 1). The phasing problem
was solved by multistep molecular replacement by using the
coordinates of the A domains of bovine factor Vai (Adams
et al., 2004) and ceruloplasmin (Zaitseva et al., 1996) and the
C2 domain of human factor VIII (Pratt et al., 1999) as search
models. The crystallized factor VIII is a heterodimer consisting
of the heavy chain (A1-A2 domains) and light chain (A3-C1-C2
domains). Several regions within the structure are poorly ordered
and were not modeled, including residues 17–43, 211–223, 334–
376, and 714–754 within the heavy chain, and residues 1649–
1690 and 1714–1724 within the light chain.
The overall structure of factor VIII can be described as a trian-
gular heterotrimer of the A domains stacked on two smaller glob-
ular C domains (Figure 1B). This structure closely resembles that
of inactivated bovine factor Va, factor Vai (Adams et al., 2004),
except that B domain-deleted factor VIII also contains the A2
domain. The A1, A2, and A3 domains each consist of two con-
nected b barrels that resemble the fold of a typical cupredoxin-
type domain (Zaitseva et al., 1996). All three A domains share
high structural homology with each other (average root-mean-
square deviation [rmsd] = 1.40 A˚). The C1 and C2 domains are
defined by a distorted b barrel and share structural homology
(rmsd = 1.09 A˚). The factor VIII C1 domain is homologous to
the C1 domain of factor Va (rmsd = 1.04 A˚), and the factor VIII
C2 domain is homologous to the C2 domain of factor Va (rmsd =
0.93 A˚), and is nearly identical to the factor VIII C2 domain deter-
mined at 1.5 A˚ resolution (rmsd = 0.73 A˚; Pratt et al., 1999;
Figure 1C). The final model includes 630 residues of the heavy
chain, 631 residues of the light chain, two Cu2+ ions, one Ca2+,
and three carbohydrate moieties. The three N-acetyl glucos-
amines are linked to Asn239 in the A1 domain, Asn1810 in the
A3 domain, and Asn2118 in the C1 domain.
Factor VIII is a copper binding protein (Bihoreau et al., 1994),
and we identified two copper ions and their binding sites inter-
nally within the A1 and the A3 domain. These are prototypic cop-
per binding sites, with nitrogen and sulhydryl ligands (Mes-
serschmidt and Huber, 1990). In the A3 domain, the copper ion
is liganded byHis1954, Cys2000, andHis2005. The copper bind-
ing site in the A1 domain is defined by His267, Cys310, and
His315 (Figure 1D). These copper ions are located near, butStructurenot at, the domain interface, indicating that their role in enhanc-
ing light chain-heavy chain interaction is indirect (Wakabayashi
et al., 2001). The positions of these copper ions suggest that
they may be important for maintaining the structural integrity of
the interdomain interface.
A single calcium binding site was located in the A1 domain.
This site is defined by carboxyl groups of Glu110, Asp116,
Asp126, Asp125, and the backbone carbonyl of Lys107 and
Glu122 (Figure 1D). This calcium ion is bound within the A1 do-
main, but may play a role in the maintenance of the C2-A1
domain interface (Wakabayashi et al., 2001).
The three A domains form a triangular heterotrimer around a
pseudo-three-fold symmetry axis, where A1 and A3 domains
serve as the base and interact with the C2 and C1 domains,
respectively (Figure 2A). The front surfaceof the triangular hetero-
trimer of the A domains is planar, whereas the back surface
is dominated by three protrusions, formed by large loops from
each domain, that create a deep groove at the center of the three
domains (Figure 2A). The C1 and C2 domains are adjacent at
the base of the triangular heterotrimer. Each C domain projects
three b-hairpin loops containing hydrophobic and basic residues
Table 1. Statistics on Diffraction Data and Structure Refinement
of B Domain-Deleted Human Factor VIII
Crystal Data Collection Data
X-ray source APS code 24
Wavelength (A˚) 0.97918
Resolution (A˚) N3.98
Space group P41212
Unit cell parameters a = b = 134.113 A˚,
c = 349.760 A˚, a = b = g = 90
Redundancy (outer shell) 13.2 (8.0)
No. of unique
reflections (outer shell)
27631 (2505)
Completeness (outer shell) (%) 99.0 (92.3)
I/s (overall/outer shell) 27.2 (1.7)
Rsym
a (overall/outer shell) (%) 13.0 (82.7)
Refinement
Resolution (A˚) 50.003.98
Rcryst
b (%) 25.56
Rfree
c (%) 32.69
Rmsds
Bond lengths (A˚) 0.017
Bond angles (deg) 1.741
APS = Advanced Photon Source; rmsd = root-mean-square deviation.
a Rsym = SjI  < I > j/SI.
b Rcryst = SjjFoj  jFcjj/SjFoj, where Fo and Fc are the observed and calcu-
lated structure factors, respectively.
c Rfree was calculated with 5% of the data excluded from the refinement
calculation.(C) Overlaid polypeptide backbone of the C2 domain of B domain-deleted factor VIII (pink) and that of the 1.5 A˚ resolution structure of the isolated C2 domain
(gray; PDB code: 1D7P; Pratt et al., 1999).
(D) Two Cu2+ binding sites and one Ca2+ binding site were identified in the B domain-deleted factor VIII. The experimental electron density maps of the metal ions
are contoured at 4s. Upper panel: Cu2+ binding site in the A1 domain. Middle panel: Cu2+ binding site in the A3 domain; each Cu2+ is liganded by two histidine and
one cysteine residue with a trigonal planar coordination geometry. Lower panel: a Ca2+ ion is liganded by carboxyl groups of aspartate and glutamate residues as
well as two backbone carbonyl oxygens.16, 597–606, April 2008 ª2008 Elsevier Ltd All rights reserved 599
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Structure of Blood Coagulation Factor VIIItoward the same plane. These loops likely contribute to the
interaction of factor VIII with the phospholipid bilayer (Figures
2B and 2C).
Although the C2 domain is connected to the C1 domain and
located adjacent to the A1 domain, there are few direct contacts
of the C2 with either domain (Figure 2D). The interface between
the C2 and A1 domains only buries 371 A˚2 of solvent-accessible
surface area. Only Arg121 from the A1 domain is in sufficient
proximity to form hydrogen bonds with the backbone carbonyl
of Leu2302 and the side chain of Gln2266, and only Glu122 is
capable of an electrostatic interaction with Lys2239 (Figure 2D,
left inset). The only close interactions between the C1 and C2
domains are observed within the loop that connects the two
domains (residues 2168–2175), and between Met2176 and
Thr2023, Val2294s and Ser2029 (Figure 2D, right inset). These
contacts cover a limited accessible surface area (344 A˚2).
Together, these observations strongly suggest the potential flex-
ibility of the C2 domain, and are in agreement with the concept
that the C2 domain undergoes conformational changes upon
proteolysis within the light chain, resulting in enhanced affinity
of factor VIIIa for anionic phospholipid surfaces (Saenko et al.,
1998).
Figure 2. Structural Features of the A and C
Domains
(A) The A1, A2, and A3 domains form a triangular
heterotrimer around a pseudo-three-fold symme-
try. Side view of the A domain heterotrimer shows
that the front surface is relatively flat when com-
pared with the back face, which contains a deep
cleft formed by three large loops.
(B) The C1 and C2 domains contain numerous
basic or hydrophobic residues positioned in the
hairpin loops at the base of the domains.
(C) As an indication of the basic and hydrophobic
nature of the putative lipid binding surface of the
C domains, the solvent-accessible surface at the
bottom of both C1 and C2 domains is colored by
electrostatic potential (±8 kT/e) computed by
APBS (Baker et al., 2001).
(D). The C2 domain has few interactions with the
A1 (left inset) and the C1 (right inset) domains.
The key residues involved in direct contact are
indicated. The loop that connects the C1 and C2
domains is highlighted with a dashed line in the
right inset.
Factor VIII and factor V are procofac-
tors that show approximately 40% se-
quence similarity and a parallel domain
arrangement in their primary structures
(Kane and Davie, 1986). Both cofactors
are activated to their active cofactor
forms, factor VIIIa and factor Va, by
thrombin-mediated limited proteolysis
(Pittman and Kaufman, 1988; Nesheim
and Mann, 1979). Both cofactors are in-
activated by activated protein C-medi-
ated limited proteolysis to yield factor
VIIIai and factor Vai. The three-dimen-
sional structure of factor V has not been
solved, thus precluding direct comparisonwith our current struc-
ture of human B domain-deleted factor VIII. However, a high-res-
olution X-ray crystal structure of activated protein C-inactivated
bovine factor Va, factor Vai, allows partial comparison, since ac-
tivation and subsequent inactivation of factor V is associated
with the removal of the B domain and the A2 domain (Adams
et al., 2004). The spatial arrangement of the A1 and A3 domains
in B domain-deleted factor VIII are nearly identical with that of
factor Vai, while the C1 and C2 domains show slightly different
conformations when comparing our factor VIII structure with
that of factor Vai. Despite the differences in the C1 and C2 do-
mains, structures of factor VIII and factor Vai can be superim-
posed with an rmsd of 1.54 A˚ for the a carbons of the 524 resi-
dues that span the A1, A3, C1, and C2 domains (Figure 3A).
The activation of factor VIII by thrombin requires cleavage of a
peptide bond in the A2 domain after Arg372, and the removal of
the B domain linked to the 41 residue N-terminal region of the A3
domain, typically referred to as the a3 acidic region (residues
1649–1689) by thrombin cleavage after Arg1689 (Pittman and
Kaufman, 1988). This exposes the factor VIII surfaces that are
important for factor IXa binding. Activation is also associated
with, but does not require, cleavage after Arg740 (Pittman and600 Structure 16, 597–606, April 2008 ª2008 Elsevier Ltd All rights reserved
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Structure of Blood Coagulation Factor VIIIFigure 3. Comparison of Factor VIII and Factor Vai and the Putative Position of the B Domain
(A) Stereo view of the X-ray crystal structure of human B domain-deleted factor VIII compared to that of factor Vai. Superimposition of the carbon backbones of B
domain-deleted factor VIII (gray) and factor Vai (yellow; PDB code: 1SDD; Adams et al., 2004). Factor Vai shares the same domain organization as B domain-
deleted factor VIII, but does not include the A2 domain.
(B) The model of the heavy chain (dark gray) ends at residue Lys713 and the light chain (light gray) starts at Phe1691. Both termini are colored green, and the
putative location of B domain is shaded in green. The region between residues 334 and 376, which includes the activation cleavage site adjacent to Arg372,
is disordered and without electron density, and was not modeled. The flanking termini of this region are colored orange. This protein face includes the known
interaction sites between factor VIIIa and factor IXa (light blue, purple, and red) based on biochemical studies. The putative membrane binding sites of the C1
and C2 domains are colored dark blue.Kaufman, 1988). In B domain-deleted factor VIII, conversion of
factor VIII to factor VIIIa requires cleavage at Arg1689 to remove
the acidic a3 region adjacent to the A3 domain as well as cleav-
age after Arg372. These regions are located on the front surface
of factor VIII (Figures 1A and 3B). Thus, it appears that the B
domain and the a3 acidic region peptide are positioned on one
face of the triangular heterotrimeric A domains of factor VIII
and obstruct a functionally significant surface on the A2 and
A3 domains (Figure 3B). This putative B domain interaction sur-
face on factor VIII includes all of the suggested factor IXa binding
regions previously described, including residues 558–565, 707–
712, and 1811–1818 (Fay et al., 1994; Jenkins et al., 2004; Lent-
ing et al., 1996).
Model of the Complex of Factor VIII and Factor IXa
The assembly of the factor IXa-factor VIIIa complex involves
binding of factor VIIIa and factor IXa on phospholipid membrane
surfaces in the presence of calcium ions. Based upon homology
modeling (Autin et al., 2005), the analysis of naturally occurring
hemophilia A and B mutations or mutations introduced by site-
specific mutagenesis (Mannucci and Tuddenham, 2001; Fay
et al., 1994; Nishimura et al., 1993; Hughes et al., 1993), cross-
linking studies (Blostein et al., 2003), and inhibition with synthetic
peptides (Lenting et al., 1996), the factor VIIIa binding surface for
factor IXa is thought to involve the A2 and A3 domains that inter-
act with multiple domains on factor IXa. The A3 domain of the
light chain contains a high-affinity binding site (Kd 2–15 nM)
for factor IXa (Bajaj et al., 2001). Inhibition studies with synthetic
peptides directed against the A3 domain have located this siteStructureto residues 1811–1818 (Lenting et al., 1996). Potential factor
IXa binding sites on the A2 domain include residues 558–565
(Fay et al., 1994) and the region around Asp712 (Jenkins et al.,
2004). We have mapped these putative binding regions onto
our structure of factor VIII (Figures 3B and 4A). All three binding
regions are solvent exposed on the front surface of the molecule
and surround a portion of the interface between the A2 and
A3 domains. One of these binding regions, residues 558–565,
bound to the C2 domain of a symmetry-related molecule in the
crystal. The crystal interaction involves mainly hydrophobic
and basic residues (e.g., Arg2215, Lys2249, Leu2251) from the
b-hairpin loops located at the bottom of the C2 domain. Despite
the fact that these interacting residues are located on different
loops of the C2 domain, their positions closely resemble those
in the a-helix region 330–339 in factor IXa (Figures 4B and 4C;
Bajaj et al., 2001). This crystal contact may be mimicking the
interaction between factor VIIIa and the 330–339 helix of factor
IXa, as suggested in previous studies (Bajaj et al., 2001).
Cleavage of the factor VIII heavy chain to the factor VIIIa heavy
chain is required to increase catalytic efficiency of factor IXa
(Fay, 2004). However, this proteolytic activation of factor VIII
appears to lead to only subtle changes in structure (Fay, 2004).
Furthermore, both porcine and human factor VIII also bind to
porcine factor IXa (Duffy et al., 1992). Based on these observa-
tions, we have constructed a model of the factor IXa-factor VIIIa
complex with our factor VIII structure and the X-ray crystal struc-
ture of the porcine factor IXa backbone with the following
constraints: (1) residues 558–565 of factor VIII interact with the
330–339 helix of factor IXa (Bajaj et al., 2001; Kolkman et al.,16, 597–606, April 2008 ª2008 Elsevier Ltd All rights reserved 601
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Structure of Blood Coagulation Factor VIII1999); (2) 707–712 of factor VIIIa bind to factor IXa residues
301–303 (Kolkman et al., 1999; Liles et al., 1997); (3) residues
1811–1819 of factor VIII interact with the light chain of factor
IXa (Lenting et al., 1996); (4) Phe25 in the Gla domain of factor
IX is juxtaposed with the light chain of factor VIII (Blostein
et al., 2003); (5) the Gla domain of factor IXa is situated within
the phospholipid membrane, forming noncovalent interactions
between the phosphoserine head group and fatty acid chains
of the phospholipid bilayer and the hydrophobic patch and the
Gla residues within the Gla domain of factor IXa (Freedman
et al., 1996; Huang et al., 2003; Figure 4A).
The program HADDOCK was used for the docking calcula-
tions (Dominguez et al., 2003). Figure 5A shows a plot of the
intermolecular energy (the sum of intermolecular van der Waals,
electrostatic, and AIR energy terms) for 60 complex structures,
after water refinement, as a function of their backbone rmsds
from the lowest energy structure. Three main clusters, labeled
‘‘1,’’ ‘‘2,’’ and ‘‘3,’’ were obtained after analysis, with a 5 A˚
rmsd cut-off to distinguish the clusters. After analyzing the rep-
resentative structures from each cluster based on the con-
Figure 4. Binding Interface between the
Complex of Factor VIII and Factor IXa
(A) Three different interaction sites with factor IXa
were identified on factor VIIIa in previous studies,
and are colored in blue, purple, and red, respec-
tively. The complementary binding sites on factor
IXa are colored accordingly. Region i (light blue)
includes residues 558–565 on factor VIIIa and
the 330–339 helix on factor IXa. Region ii (purple)
includes residues near 712 on factor VIIIa and
residues 301–303 on factor IXa. Region iii (red)
on factor VIIIa represents the binding site (1811–
1818) that has been suggested to be responsible
for the high-affinity interaction between factor VIIIa
and factor IXa. Residues on the light chain of factor
IXa that have been shown to be important for bind-
ing include Phe25 (red) within the factor IXa Gla
domain, which is known to be juxtaposed to the
factor VIIIa light chain, Tyr69 (red; Nishimura
et al., 1993) and Asn92 (red; Hughes et al., 1993).
The putative binding region on factor IXa that
interacts with residues 1811-1818 of factor VIII is
highlighted with a dashed line. The putative phos-
pholipid binding sites in the C1 and C2 domains of
factor VIIIa and the Gla domain of factor IXa that
are responsible formembranebindingare indicated
(dark blue).
(B) Positions of residues contributed from different
loops of the C2 domain resemble that of the 330–
339 a helix of factor IXa.
(C) Stereo view of superimposition of loops of the
C2 domain of factor VIII and that of the 330–339
a helix of factor IXa.
straints described above, the representa-
tive structure from cluster 1 provided the
best model of the factor IXa-factor VIIIa
complex. Cluster 1 contains the overall
lowest energy structures; the average
rmsd values relative to the lowest energy
structure is 1.37 ± 0.96 A˚. Both factor VIIIa
and factor IXa in the model of this complex maintain the same
overall fold as in their crystal structures. The model of the factor
IXa-factor VIIIa complex illustrates that the light chain of factor
IXa, which includes the phospholipid binding Gla domain, is
wrapped across the side of the A3 domain of factor VIII, and is
on the opposite side from the membrane binding interface of
the complex from the C2 domain, which is important for factor
VIIIa interaction with the membrane (Figure 5B). This orientation
of the factor VIII light chain and factor IX Gla domain suggests
that the C2 domain of factor VIII in our model is above the mem-
brane surface, and has to undergo a significant conformational
change in order to orient its membrane binding surfaces in the
same direction as the Gla domain of factor IXa (Figure 5C). In
fact, in addition to our observation that the C2 domain must
undergo a conformational change upon activation, the 15 A˚
resolution cryoelectronmicroscopy structure of factor VIII bound
to phospholipids shows that the A domains are inclined at an
angle of 60–65 to the membrane surface, with the A3 domain
positioned close to the membrane surface (Stoylova et al.,
1999). Furthermore, factor IXa has been shown to orient with602 Structure 16, 597–606, April 2008 ª2008 Elsevier Ltd All rights reserved
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Structure of Blood Coagulation Factor VIIIFigure 5. Model of the Factor IXa-Factor VIIIa Complex
(A) Plot of the intermolecular energy as a function of the rmsd from the lowest energy structure for the factor IXa-factor VIIIa complex. Three major clusters were
identified, labeled 1, 2, and 3. The values for individual conformations (open squares) and the averages of the clusters (red diamonds) are shown.
(B) Front and side views of the complex of factor VIIIa (heavy chain [dark gray] and light chain [light gray and gray]) and factor IXa (heavy chain [orange] and light
chain [yellow]). Four putative membrane binding sites, including the bases of C1 and C2 domains, the A3 domain loop of factor VIII, and the Gla domain of factor
IXa, lie on the same plane (blue). The active site of factor IXa is indicated (red).
(C) Stereo view diagram of the possible interaction of the factor IXa-factor VIIIa complex with phospholipid membrane surfaces.the long axis of the molecule perpendicularly to the membrane,
with the Gla domain proximal to the membrane and the active
site positioned more than 70 A˚ above the surface (Mutucumar-
ana et al., 1992). We suggest that, upon binding to factor IXa,
the C2 domain of the phospholipid-bound factor VIIIa undergoes
a significant conformational change that alters the orientation
of the factor VIIIa from an upright position to a bent position, in
order for the Gla domain of the bound factor IXa to interact
with the phospholipids membrane simultaneously (Figure 5C).
The active site of factor IXa in this model of the factor IXa-factor
VIIIa complex is positioned on the top of the complex facing into
the solution, with an approximate distance of 75–80 A˚ above the
membrane surface.
We have identified four putative phospholipid binding sites in
the factor IXa-factor VIIIa complex. Pratt et al. (1999) have previ-
ously identified the loops in the C2 domain of factor VIII as likely
participants in phospholipid binding. Within the context of the
domain organization of C2 in the factor IXa-factor VIII complex,
Arg2215 and Lys2249 play a special role. The hairpin loops in the
factor VIII C1 domain, including Arg2090, Lys2092, and Arg2159,
likelyplaya similar role, aspredictedpreviously (Liuet al., 2000). In
addition, a well-defined loop extends downward from the back-
side of the factor VIII A3 domain (Figure 5C). This loop, whichStructureincludes a b turn, is held together by Cys1899 and Cys1903,
and thrusts Arg1900 into a favorable position for electrostatic in-
teraction with acidic phospholipid headgroups. The polypeptide
backbone of this loop is structurally similar to the omega loop of
the Gla domain of factor IXa. With the prothrombin Gla domain
as a prototype, we have previously established that the phospho-
serine head group in lysophosphatidylserine interacts with con-
served residues within the Gla domain of vitamin K-dependent
proteins, including factor IX (Huang et al., 2003). Trp4 within the
omega loop of the Gla domain of prothrombin is located 5–7 A˚
below the membrane surface in the interfacial membrane region
(Falls et al., 2001). Based on this observation, the factor IXa in
this model was similarly positioned.
An intermediate resolution X-ray crystallographic structure
of biologically active B domain-deleted human factor VIII has re-
cently been reported, although the coordinates of this structure
are not yet available (Shen et al., 2008). The general, overall
structure appears similar to our own, specifically the domain or-
ganization. Oneminor difference is that we only identified a single
calcium binding site, whereas Shen et al. located two sites. Both
of these structures are at similar resolution, and the crystals are
characterized by the same space groups. Understanding of the
domain organization, the metal binding sites, and the surface16, 597–606, April 2008 ª2008 Elsevier Ltd All rights reserved 603
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Structure of Blood Coagulation Factor VIIIfeatures in this protein, as well as its membrane binding proper-
ties, will contribute to the study of the structure-function relation-
ships in the mutations of hemophilia and the assembly of prote-
ases associated with protein cofactors. Furthermore, the model
of the factor IXa-factor VIIIa complex and its interaction with
membrane surfaces are critically important to detailed under-
standing of normal hemostasis within the context of the blood
coagulation cascade. Knowledge of the structure of factor VIII
may also be useful for the design of improved therapies for
hemophilia A or venous thromboembolic disorders.
EXPERIMENTAL PROCEDURES
Expression and Purification of B Domain-Deleted Factor VIII
B domain-deleted recombinant factor VIII (Wyeth) was prepared as previously
described (Sandberg et al., 2001; Eriksson et al., 2001) with the followingmod-
ifications. Chinese hamster ovary cells were cultured in medium free of human
serum albumin, and purification by monoclonal antibody immunoaffinity chro-
matography was replaced with peptide ligand affinity chromatography with
TN8.2 Sepharose (Kelley et al., 2004). The purified factor VIII used for crystal-
lization was obtained detergent free following the anion exchange step used
in the manufacturing process. Purified factor VIII, at a concentration of
2.5mg/ml in 50mMhistidine (pH 6.3), 4mMCaCl2, 400mMNaCl, was stored
at 80C.
Formation of B Domain-Deleted Factor VIII Crystals
and Data Collection
Crystals were obtained by hanging drop vapor diffusion at 25C by the Hamp-
ton screen (Hampton Research). The drop contained 1 ml of factor VIII at
10 mg/ml mixed with 1 ml of reservoir solution. The optimal condition for crys-
tallization was found to be 100 mM Tris-HCl (pH 8.5), 10% ethanol, and 7%
PEG 3350 in the reservoir. All crystals were cryoprotected by sequential addi-
tion of 10%, 15%, and, finally, 20% ethylene glycol (v/v) in the presence of the
reservoir solution and flash frozen in liquid nitrogen prior to data collection.
Factor VIII crystallized in a P41212 space group (a = b = 134.113 A˚,
c = 349.760 A˚, and a = b = g = 90) with one molecule per asymmetric unit.
X-ray diffraction data of factor VIII crystals were collected at the National
Synchrotron Light Source at Brookhaven National Laboratory and the
Northeastern Collaborative Access Team synchrotron beamline 24 of the
Advanced Photon Source (APS) at Argonne National Laboratory. All X-ray
data were processed using program HKL2000 (Otwinowski and Minor, 1997;
Table 1).
Structure Determination and Refinement of Factor VIII
For structural determination by the molecular replacement method, a homol-
ogy structure model of factor VIII was constructed from the known primary
sequence of factor VIII (Schwede et al., 2003) with the template structures of
factor Vai (PDB code: 1SDD; Adams et al., 2004) and ceruloplasmin (PDB
code: 1KCW; Zaitseva et al., 1996). The structures of the A1 and A2 domains
of factor VIII were initially determined with AMoRe (Navaza, 1994) with the A1
and A2 domains of the homology model. This yielded clear rotation function
and translation function solutions. The A3 domain was then solved by AMoRe
after fixing the solution of the A1 and A2 domains and by using the A3 domain
of ceroluplasmin as a search model (PDB code: 1KCW; Zaitseva et al., 1996).
After fixing all three A domains together, the positions of the C1 and C2 do-
mains were determined with the program PHASER with a polyalanine model
built from the high-resolution structure of the C2 domain of factor VIII (PDB
code: 1D7P; Pratt et al., 1999; McCoy, 2007). The structure was refined with
several cycles of manual refitting and refinements with REFMAC of the
CCP4i suite (Murshudov et al., 1997; Potterton et al., 2003). The Rcryst and Rfree
for the factor VIII model were 25.70% and 33.06%, respectively, for data from
50–3.98 A˚ (Table 1).
Modeling of the Factor VIIIa-Factor IXa Complex
Human factor IXa was constructed by homology modeling with the X-ray
structure of porcine factor IXa (PDB code: 1PFX) and the program SWISS-604 Structure 16, 597–606, April 2008 ª2008 Elsevier Ltd All rights rMODEL (Schwede et al., 2003; Brandstetter et al., 1995). The structure of fac-
tor VIIIa was docked with factor IXa with the program HADDOCK (Dominguez
et al., 2003). In this approach, residues previously reported to be important for
factor VIIIa-factor IXa interactions were defined as the ambiguous interaction
constraints. Initially, 600 structures for the complex were generated by dock-
ing factor VIII and factor IXa as rigid bodies, and 60 of those were followed
by semirigid, simulated annealing in torsion angle space, and analyzed with
the default settings at all stages. The resultant structures were clustered.
The best model was selected based on the convergence of the structures
with the largest binding interface and the lowest intermolecular energy while
satisfying the constraints defined by previous studies.
ACCESSION NUMBERS
Coordinates have been deposited in the Protein Data Bank with accession
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